EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
BioNTech (NASDAQ:BNTX) to Buyback $1.00 billion in Shares
Other news to note for May 7, 2026 | BioWorld
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides
Wells Fargo & Company Cuts BioNTech (NASDAQ:BNTX) Price Target to $140.00
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year | Morningstar
Health Care Up After Earnings - Health Care Roundup | Morningstar
BioNTech Q1 Earnings Call Highlights
BioNTech (NASDAQ:BNTX) Announces Earnings Results - Zolmax
BioNTech to cut up to 1,860 jobs as Covid jab sales drop
BioNTech (NASDAQ:BNTX) Posts Earnings Results, Beats Estimates By $0.26 EPS - Daily Political
BioNTech (BNTX) Is Down 7.5% After Tariff Jitters, Leadership Shifts And Cut Guidance Reset - Has The Bull Case Changed?
BioNTech Faces Tariff Risks And Leadership Shift As Oncology Plans Advance
BioNTech (NASDAQ:BNTX) Shares Gap Down - What's Next?
CureVac targets Moderna with 10-patent suit over Spikevax
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Tuesday
BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE
BioNTech (BNTX) - Research Analysts' Recent Ratings Updates - Daily Political
BioNTech Stock Forecast | Co-Founder Exit, 2026 Guidance Cut | Capital.com
HC Wainwright Reaffirms "Buy" Rating for BioNTech (NASDAQ:BNTX)
BNTX Reiterates by HC Wainwright & Co. -- Price Target Maintaine
CureVac sues Moderna for patent infringement over COVID-19 vaccines
BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models
Sierk Poetting Sells 50,000 Shares of BioNTech (NASDAQ:BNTX) Stock
Why BioNTech (BNTX) Is Up 9.2% After Strong Phase 2 HER2 ADC Data In Endometrial Cancer
BioNTech (BNTX) Price Target Raised Following Successful T-Pam Data
BioNTech (NASDAQ:BNTX) COO Sierk Poetting Sells 50,000 Shares - Daily Political
BioNTech (BNTX) Is Up 13.4% After Positive HER2 Endometrial Cancer Phase 2 Data Release
BNTX: Leadership Turnover And Weak COVID Outlook Will Pressure Future Expectations
BioNTech (BNTX) Gains Investor Interest Following Promising ASCO Presentation
Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum
BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX
BioNTech's (BNTX) Buy Rating Reiterated at Berenberg Bank - Daily Political
BioNTech (BNTX) Is Up 9.8% After Strong Phase 2 HER2 ADC Data - Has The Bull Case Changed?
Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Target Price at $133.13 - Stock Observer
BioNTech (NASDAQ:BNTX) Earns "Buy" Rating from Berenberg Bank - Stock Observer
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data
BioNTech announce Phase 2 cohort of BNT323 met primary efficacy endpoint | Markets Insider
BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer | Taiwan News | Apr. 11, 2026 19:00
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts
BioNTech (NASDAQ:BNTX) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Aberdeen Group plc Lowers Stock Position in BioNTech SE Sponsored ADR $BNTX
How The BioNTech (BNTX) Story Is Shifting With New Leadership And Post COVID Pipeline Bets
BioNTech news
Latest news
Show moreZelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks
Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets
Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty
